natgillin/translations-raw huggingface dataset:
In a practical preferred embodiment of the invention, the scaffold is formed by a matrix of interconnected growth surfaces spaced at regular intervals around a central support. 
Uređaj u skladu s patentnim zahtjevom 1 pri čemu je podij oblikovan matriksom međusobno povezanih površina rasta razmaknutih u pravilnim intervalima oko središnje potpore.
The separator is preferably a contrast colour, such as blue, to a colour of the tissue. 
Sklop posude prema bilo kojem od prethodnih Zahtjeva, gdje je separator (31) kontrastne boje, poput plave, u odnosu na boju tkiva.
The composition according to any one of the preceding claims, wherein the at least one polymer resin is selected from the group comprising halogenated polymer resins, styrenic resins, acrylic resins, polyolefines, polycarbonate resins, unsaturated polyester resins, polyurethane resins, polyamide resins and mixtures thereof, preferably the polymer resin is PVC. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time da barem jedna polimerna smola je odabrana 1z skupine koja sadrži halogenirane polimerne smole, stirenske smole, akrilične smole, poliolefine, polikarbonatne smole, smole nezasićenih poliestera, poliuretanske smole, poliamidne smole te njihove smjese, poželjno polimerna smola je PVC.
and R10, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms, Y is OH 
može biti vodik, alkil-skupina koja ima od 1 do 5 atoma ugljika, COR', COOR’, CON(R')(R"), s R' i R" koji mogu biti međusobno isti ili različiti, a predstavljeni su vodikom i alkil-skupinom koja ima od 1 do 5 atoma ugljika,
the precipitation bath comprises at least one of an aqueous acidic solution, an aqueous alkali solution, and/or an alcohol. 
(b) taložena otopina sadrži najmanje jednu od vodene kiselinske otopine, vodene alkalne otopine i/ili alkohola.
CRL-9096 (CHOdhfr-) when expressed therein, and wherein the protein molecules have at least one of the glycosylation characteristics (i) to (viii). 
CRL-9096 (CHOdhfr-) kada se tamo eksprimira, te gdje molekule proteina imaju najmanje jednu od značajki glikoziliranja (i) do (viii).
A pharmaceutical composition for use in treating multiple sclerosis, the composition comprising: 
Farmaceutski pripravak za upotrebu u liječenju multiple skleroze, naznačen time da se pripravak sastoji od:
An AAV vector comprising a gene of interest for use in a method for delivering the gene to motor neurons or glial cells by peripheral administration of said AAV vector to a subject in need thereof, wherein said AAV vector is a human AAV10 vector or a human AAV9 vector. 
AAV vektor koji sadrži gen od interesa za uporabu u metodi za dostavu navedenog gena od interesa motoričkim neuronima ili glija stanicama intraperitonealnim (i.p.), intramuskularnim (i.m.) ili intravenskim (i.v.) injiciranjem, poželjno intravenskim injiciranjem, navedenog AAV vektora subjektu, pri čemu je navedeni AAV vektor:
an isolated IL-23p19 antibody comprising: 
Izolirano IL-23p19 antitijelo, koje sadrži:
Another object of the invention is an antibody whose sequence comprises the polypeptide sequences SEQ ID NO: 2 and 4. 
- teški lanac koji sadrži polipeptidnu sekvencu SEQ ID NO: 2 i laki lanac koji sadrži polipeptidnu sekvencu SEQID NO: 4, -
The method of claim 1, wherein the patient is a human. The method of claim 1, wherein at least a portion of the compound is present as a crystalline form having an X-ray diffraction pattern (CuKa) comprising significant diffraction peaks at about 8.8, 12.9, 13.4, 14.2 and 17.4° 2θ. 
Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je u najmanju ruku dio spoja prisutan kao kristalni oblik s uzorkom difrakcije rendgenskih zraka (CuKa) koji sadrži značajne difrakcijske maksimume na otprilike 8,8, 12,9, 13,4, 14,21 17,4" 26.
has a heavy chain that comprises the amino acid sequence of SEQ ID NO:25 or a sequence having at least 80% sequence identity thereto and/or a light chain that comprises the amino acid sequence of SEQ ID NO:26 or a sequence having at least 80% sequence identity thereto, preferably said antibody 
ima teški lanac koji ima aminokiselinski slijed sa SEQ ID NO:25 ili slijed koji je najmanje 80 % istovjetan tom slijedu i/ili laki lanac koji ima aminokiselinski slijed sa SEQ ID NO:26 ili slijed koji je najmanje 80 % istovjetan tom slijedu, gdje po mogućnosti navedeno protutijelo
Within that same portion 22 of the base member 2 there is housed a drip pan (not shown) for collecting possible liquid leaking from the functional unit 10 or the vessel intended to receive the beverage, as well as residues of raw material (coffee grounds) that remain in the capsule upon the beverage having been dispensed. 
U istom dijelu 22 osnovnog elementa 2 smještena je posudica za prikupljenje kapi (nije prikazana), koja prikuplja tjekućinu koja bi mogla curiti iz funkcionalne jedinice 10 ili posuda namijenjena za primanje napitka, kao 1 ostaci sirovine (mljevena kava) zaostale u kapsuli nakon isporučivanja napitka.
A composition comprising a bacterial strain of the genus Blautia, for use in a method of treating or preventing diarrhea associated with Enterobacteriaceae infection. 
Kompozicija za upotrebu prema zahtjevu 1 pri čemu je dijareja povezana sa infekcijom Enterobacteriaceae.
obtaining an image of a droplet (2100) of said dosage of active agent (2000) that will be dispensed onto each of said plurality of carrier substrates (1000), wherein said image of said droplet (2100) is taken in-flight; 
snima sliku kapi (2100) navedene doze aktivnog sredstva (2000) koju će se izdati na svaki od navedenih više nosivih supstrata (1000), gdje se navedenu sliku navedene kapi (2100) snima u letu;
The electrode compartment comprises a connection to supply fuel or an oxidator, for example oxygen, to the compartment. 
Odjeljak elektrode sukladno zahtjevu 1 ili 2, naznačen time što ovaj uključuje sustav opskrbe za opskrbu odjeljka kisikom.
Alternatively, according to another embodiment of the invention, the mobile terminal may also transmit scheduling-related information for uplink scheduling on the assigned uplink resources. 
Komunikacijska metoda sukladno zahtjevu 2, naznačena time da se izvješćivanje o CQI provodi na resursima uzlazne veze koji su dodijeljeni informacijama o raspoređivanju resursa.
providing a composition comprising an alkylaluminum compound, a chromium compound, and a hydrocarbon solvent selected from the group consisting of C8- C11 alkane compounds having one branch, n-undecane, and combinations thereof, and contacting ethylene with the composition to provide a solution comprising 1-hexene and polyethylene, wherein the polyethylene has a melting point of less than 125.4°C. 
Postupak priprave 1-heksena, naznačen time što se sastoji u: osiguravanju smjese koja sadrži alkilaluminijev spoj, spoj kroma, te ugljikovodično otapalo kojeg se bira iz skupine koju čine C8-C11 alkanski spojevi s jednom granom, n-undekan, te njihove kombinacije, i stavljanju u kontakt etilena sa smjesom kako bi se dobilo otopinu koja sadrži 1-heksen i polietilen, gdje polietilen ima talište ispod 125,4 *C.
A process according to claim 1 wherein the emulsion or dispersion comprises at least one active principal or a precursor thereof, and a carrier substance. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu emulzija ili disperzija obuhvaća najmanje jednu aktivnu osnovu ili njen prekursor i tvar koja je nosač.
More preferably, the hydrogen chloride is added as gaseous hydrogen chloride. 
Još poželjnije, klorovodik se dodaje kao plinoviti klorovodik.
As shown in FIG. 2B, the container 101 is inverted and may rest on the cap 200 . 
Kako je prikazano na Slici 2B, posuda 101 je okrenuta i može stajati na poklopcu 200.
A biomass pyrolysis process according to claim 1, wherein vapour and/or gaseous products of the biomass pyrolysis process are provided to an inlet of a biomass gasification process. 
Postupak plinofikacije koji obuhvaća postupak pirolize biomase prema bilo kojem od zahtjeva 1 do 5, naznačen time, da se parni i/ili plinoviti produkti iz postupka pirolize biomase dobivaju na ulaznom dijelu postupka plinofikacije biomase.
The use according to any one of claims 26 to 33, wherein said anti-C5 antibody is eculizumab or pexelizumab; wherein said inhibitor of IL-2 is selected from the group consisting of cyclosporine A, tacrolimus, and sirolimus; and wherein said immunosuppressive drug is LF15-0195. 
Uporaba prema bilo kojem od zahtjeva 26 do 33, naznačena time, što je spomenuto anti-C5 antitijelo ekulizumab ili pekselizumab; pri čemu se spomenuti inhibitor IL-2 bira iz grupe koja se sastoji od ciklosporina A, takrolimusa i sirolimusa; i pri čemu je spomenuti imunosupresivni lijek L.IF15-0195.
A compound according to any of claims 1 to 7 or a composition according to claims 8 or 9 for use in the treatment or prevention of a disorder or disease associated with a RyR that regulates calcium channel functioning in cells. 
Uporaba spoja prema patentnom zahtjevu 1 ih 2 za liječenje ili prevenciju poremećaja ili bolesti povezanog/povezane sa RyR koje regulira funkcioniranje kalcijevih kanala u stanicama.
a light chain and/or a heavy chain of the antibody or antigen binding fragment thereof of any one of claims 1 to 9. 
Nukleinska kiselina, naznačena time, da ona kodira varijabilno područje lakog lanca i varijabilno područje teškog lanca od protutijela ili njegovog fragmenta koji veže antigen u skladu s bilo kojim od zahtjeva 1 do 6.
The pharmaceutical composition of any one of claims 2 to 8, wherein the pharmaceutical composition is to be administered intravenously in an amount of 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 7, gdje se farmaceutska kompozicija treba administrirati intravenski u količini od:
The isolated antibody or antibody fragment thereof for use according to claim 5 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, and graft-versus-host disease. 
Izolirano protutijelo za uporabu prema zahtjevu 8, naznačeno time da je navedena autoimuna bolest odabrana iz skupine koja se sastoji od reumatoidnog artritisa, sistemskog eritemskog lupusa, upalne bolesti crijeva, ulcerativnog kolitisa i bolesti presatka protiv domaćina.
condensing an a, B-unsaturated ketone derivative represented by the formula (VII): wherein R3, X and m are as defined above, and the compound of the above formula (V); 
(DV) (Vii) pri čemu su R*, X i m kao što je definirano gore, a spoj sa gore navedenom formulom (V);
This pump can be equipped with a means to regulate flow, so that the amount of additive discharged to the crop is matched to the rate of harvest, and the desired ratio of application can be maintained. 
Ova pumpa može biti opremljena sredstvima za reguliranje protoka tako da je količina aditiva ispuštena na usjev prilagođena brzini žetve, tako da se može održavati željena brzina nanošenja.
Reagent diluent prepared by adding 0.1% BSA and 0.05% Tween-20 in PBS instead of Tris-buffered Saline. 
- = Razrjeđivač uzoraka je priređen dodavanjem 0.1% BSA i 0.05% Tween-20 u PBS-u umjesto u slanoj otopini koja je puferirana s Trisom.
Substrates, especially particulates, may be placed within a container, preferably formed from a metallic foil. 
Supstrati, naročito čestični, mogu biti postavljeni unutar kontejnera, koji je poželjno formiran od metalne folije.
The total intracellular cAMP concentration was quantitated using the Amersham cAMP SPA kit. 
Ukupna intracelularna cAMP koncentracija određena je primjenom kita Amersham cAMP SPA.
and R4, taken together with the adjacent nitrogen atom, form an azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl, or piperazinyl ring, the piperidinyl ring being optionally substituted with one or two methyl group(s) and the piperazinyl ring being optionally substituted on the other N-atom with a methyl, benzyl or phenylsulfonyl group; or a pirrolidinyl, piperidinyl, morpholinyl, or piperazinyl ring fused with a benzene ring; 
i R4, uzeti zajedno sa susjednim dušikovim atomom tvore azetidinilni, pirolidinilni, morfolinilni, piperidinilni ili piperazinilni prsten, a piperidinilni prsten može biti supstituiran s jednom ili dvjema metilnim skuinama, te piperazinilni prsten može biti supstituiran na drugom N-atomu s metilnom, benzilnom ili fenilsulfonilnom skupinom; ili pirolidinilni, piperidinilni, morfolinilni ili piperazinilni prsten fuzioniran s benzenskim prstenom;
1M L-Selectride® in tetrahydrofuran (135 ml, 135 mmol, 2.87 eq.) was added slowly over 30 minutes to a stirred solution of tetrabenazine RR / SS racemate (15 g, 47 mmol) in ethanol (75 ml) and tetrahydrofuran (75 ml) at 0 °C. After addition was complete the mixture was stirred at 0 °C for 30 minutes and then allowed to warm to room temperature. 
oo O ČELO IM L-Selectride* u tetrahidrofuranu (135 ml, 135 mmol, 2.87 ekvivalenta) se polagano tijekom 30 minuta dodaje u miješanu otopinu tetrabenazin RR/SS racemata (15 g, 47 mmol) u etanolu (75 ml) i tetrahidrofuranu (75 ml) na 0*C.
A compound of Formula (I) or a therapeutically acceptable salt thereof, wherein R1, R2, and R3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, cyano, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, NRARB, and (NRARB)carbonyl; 
, R2, i R3 su neovisno odabrani iz skupine koja se sastoji od vodika, alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, cijano, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, nitro, NRARB i (NRARB)karbonila;
preparing an aqueous solution comprising 7.9% whey protein, a calcium concentration of 0.0 to 1.4 mM, and a pH value of 8; 
(i) pripremu vodene otopine koja sadrži 7.9% proteina sirutke, kalcij u koncentraciji od 0.0 do 1.4 mM 1 ima pH vrijednost 8;
Treated with the Control compound example (12) 
Liječeni sa spojem iz primjera (12)
The plant cultivation system according to any one of claims 1 to 10, which further comprises a plant cultivation support disposed on or above said nonporous hydrophilic film. 
Sustav za uzgoj biljaka prema bilo kojem od zahtjeva 1 do 6, koji dalje obuhvaća potporu za uzgoj biljaka (4) koja se nalazi na tom neporoznom hidrofilnom sloju (1).
Panel according to at least one of the preceding claims, wherein the light fastness according to grey wool scale EN 20 105 of the surface layer (1) is higher than 2. 
primjenu tlaka i temperature u stanici za prešanje radi stvrdnjavanja navedenog najmanje jednog veziva (3) radi oblikovanja površinskog sloja (1) na podlozi (10).
diseases with pigmentation disorders and especially benign dermatoses such as vitiligo, albinism, melasma, lentigo, ephelides, melanocytic naevus and all post-inflammatory pigmentations; and also pigmented tumours such as melanomas and their local (permeation molecules), regional or systemic metastases; 
– bolesti s poremećajem pigmentacije, a osobito dobroćudnih dermatoza, poput vitiliga, albinizma, melazme, lentiga, sunčanih pjega, melanocitnog madeža i svih poslijeupalnih pigmentacija; a također i pigmentiranih tumora, poput melanoma i njihovih lokalnih (permeacijskih molekula), regionalnih ili sistemnih metastaza;
Described herein are compounds of formula I, or diastereomers or enantiomers thereof, or pharmaceutically acceptable salts of formula I or diastereomers or enantiomers thereof, or mixtures thereof: 
Spoj sa formulom I, ili njegovi diastereomeri ili enantiomeri, ili farmaceutski prihvatljive soli sa formulom I ili njihovi diastereomeri ili enantiomeri, ili njihove smjese:
Door closing hinge according to claim 5, wherein said at least one first front face (35", 36") and at least one first contact surface (37", 38") are substantially parallel to each other in said closed door position and substantially perpendicular to each other in said open door position, said at least one second front face (45") and at least one second contact surface (46") being substantially perpendicular to each other in said closed door position and substantially parallel to each other in said open door position. 
Spojnica za zatvaranje vrata prema zahtjevu 5, gdje su to barem jedno prvo prednje lice (35", 36") i barem jedna prva kontaktna površina (37", 38") u biti međusobno paralelni u zatvorenom položaju vrata i u biti međusobno okomiti u položaju otvorenih vrata, barem jedno drugo prednje lice (45") i barem jedna druga kontaktna površina (46") su u biti međusobno okomiti u zatvorenom položaju vrata 1 u biti međusobno paralelni u položaju otvorenih vrata.
e. the valve 134, will be closed. 
ventil 134, je zatvoren.
the time value (TV) stored in said time value storage means (TVSM) is updated to correspond to the date/time of storing of said most recent data element; and 
- vremenska funkcija (TV) pohranjena u navedenom sredstvu za pohranu vremenskih funkcija (TVSM) se ažurira sukladno datumu/vremenu pohrane posljednjeg podatkovnog elementa (u nizu jedna za drugom); i
m is 1 or 2, in free form or in salt form, and, where possible, in acid addition salt form. 
-N-+CH350-R,, | gdje Ra je benzil ili feniletil; i mje lili 2, u slobodnom obliku ili u obliku soli, i, gdje je to moguće, u obliku kiselinske adicijske soli.
A head according to claim 1, characterized in that said transversal direction is a rectilinear direction. 
Glava u skladu s patentnim zahtjevom 1, naznačena time, da je navedeni poprečni smjer pravocrtni smjer.
The filtration device of claim 6, wherein the mixture M comprises: 
Tkanina u skladu s patentnim zahtjevom 7, pri čemu smjesa M sadrži:
A pharmaceutical composition comprising a compound according to any one of claims 1 to 18 and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži spoj prema patentnom zahtjevu 1 ili 2 i farmaceutski prihvatljiv nosač.
The lines 6 are merely imaginary aids to show where the tool, particularly the saw, needs to be guided over the plate-shaped composite structure. 
Linije 6 su samo zamišljeno pomoćno sredstvo da se pokaže kuda se mora voditi alat, posebno pilu preko pločaste kompozitne strukture.
the antibody is suitable for administering at an effective amount of about 0.001-50 mg/kilogram of said cells, tissue, organ or animal; 
protutijelo je pogodno za davanje u učinkovitoj količini od oko 0, 1-100 mg/kilogramu navedene životinje; ili
Process according to claim 1, wherein, before said step c), the mold is covered at least partially by a material in order to confer special aesthetic effects on the surface of the final product. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da, se prije spomenutog koraka c), kalup barem djelomično prekriva s materijalom, kako bi se na površini konačnog proizvoda izveli posebni estetski efekti.
The process of claim 5, characterised in that adsorption, membrane, incineration or other technologies are used in the purification step. 
Proces prema patentnom zahtjevu 5, naznačen time, da so u stupnju pročišćavanja koriste adsorpcijska, membranska, incineracijska ili druge tehnologije.
and wherein R1, R2, R3, R4, R5, R6, R7, and R8 are independently selected from the group consisting of H, OH, alkyl, and aryl, providing that at least one of Y1, Y2, Y3, Y4, and Y5 is different from S. 
i u čemu se R1, R2, R3, R4, R5, R6, R7 i R8, nezavisno odabiru iz skupine koja se sastoji od H, OH, alkila i arila, uz uvjet da je barem jedan od Y1, Y2,Y3,Y4 i Y5 različit od S.
a binder selected from polyvinylpyrrolidone, polyethylene glycols, co-polymers of vinyl acetate and vinylpyrrolidone, potato starch and corn starch, and a combination thereof; 
vezivo odabrano od polivinil-pirolidona, polietilen-glikola, kopolimera vinil-acetata i vinil-pirolidona, krumpirovog škroba i kukuruznog škroba, i njihovih kombinacija;
transmit, in a first-in-time OFDM symbol of said first or second downlink subframe, downlink control signalling in a first set of subcarriers of said First-in-time OFDM symbol and dedicated user data in a second set of subcarriers of said First-in-time OFDM symbol. 
slanje, u prvom po redu OFDM simbolu navedenog prvog ili drugog polukadra silazne veze, kontrolnog signaliziranja silazne veze u prvom kompletu podnosilaca navedenog prvog po redu OFDM simbola i namjenskih podataka o korisniku u drugom kompletu podnosilaca navedenog prvog po redu OFDM simbola.
the single nucleotide polymorphism marker having a T at the position corresponding to position 82 in SEQ ID NO: 6, 
marker polimorfizma jednostrukog nukleotida koji ima T na položaju koji odgovara položaju 82 u SEQ ID NO: 6, i
A pharmaceutical composition containing at least one derivative according to any one of claims 1 to 13 and a pharmaceutically acceptable carrier, diluent or excipient thereof. 
Farmaceutski sastav, naznačen time da sadrži najmanje jedan derivat prema bilo kojem od patentnih zahtjeva od 1 do 13 i njegov farmaceutski prihvatljivi nosač, diluent ili ekscipijent.
The tubular member further comprises a second guiding passage 11 extending substantially longitudinal from a location 12 near the proximal end or from the proximal end 6 to the distal end 7 of the tubular member, the second passage being suitable for receiving and guiding a second endoscopic instrument 3 (needle). 
Cijevni element nadalje sadržava drugi prolaz za vođenje 11 koji se prostire uglavnom uzdužno od položaja 12 koji se nalazi uz bliži kraj ili od bližeg kraja 6 do udaljenijeg kraja 7 cijevnog elementa, pri čemu je drugi prolaz prikladan za prihvaćanje i za vođenje drugog endoskopskog instrumenta 3 (igle).
The pharmaceutical composition according to claim 5, wherein the perforated microstructures comprise a spray dried emulsion of perfluorooctyl bromide, DSPC (1,2-disteroyl-sn-glycero-3-phosphocholine) and calcium chloride in water. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što perforirane mikrostrukture sadrže emulziju perfluoroktil-bromida, DSPC (1,2-disteroil-sn-glicero-3-fosfokolin) i kalcijevog klorida osušenih raspršivanjem u vodi.
a cancer antigen binding domain; 
(1) domenu za vezanje na tumorski antigen;
The multispecific antigen-binding molecule of claim 3, wherein the first and second polypeptides further comprise an antibody H chain constant region, and the third and fourth polypeptides comprise an antibody L chain constant region. 
prvi i drugi polipeptid nadalje obuhvaćaju konstantno područje H-lanca protutijela, a treći i četvrti polipeptid obuhvaćaju konstantno područje L-lanca protutijela; ili
Method for the preparation of aqueous dispersions of claim 13) in which in step iii) the chain extender B) is added in such an amount that between 5 and 50% of free NCO groups contained in the prepolymer A) react with it. 
Postupak priprave vodenih disperzija u skladu s patentnim zahtjevom 13), naznačen time što se u koraku iii) produljivač lanca B) dodaje u takvoj količini da između 5 i 50% slobodnih NCO skupina koje sadrži prepolimer A) reagira s njim.
These and other objects, which will be apparent to a skilled person from the present disclosure, are achieved by the different aspects of the invention as defined in the appended claims and as generally disclosed herein. There is, in one aspect of the invention, provided a modified sulfamidase comprising substantially no epitopes for glycan recognition receptors, thereby enabling transportation of said sulfamidase across the blood brain barrier of a mammal, wherein said sulfamidase has catalytic activity in the brain of said mammal. 
HR P20181507 T1 PATENTNI ZAHTJEVI Modificirana sulfamidaza koja u osnovi ne sadrži epitope za receptore za prepoznavanje glikana, pri čemu su prirodni glikan dijelovi navedene sulfamidaze poremećeni pojedinačnim prekidima vezanja i dvostrukim prekidima vezanja, opseg jednostruke veze pauze na ukupne prekide su najmanje 60 % za oligomanoznim glikanima, čime se omogućuje transport navedene sulfamidaze putem krvne-moždane barijere sisavaca, pri čemu navedena sulfamidaza ima katalitičku aktivnost u mozgu spomenutog sisavca.